Neutralizing CD47-SIRPα axis with anti-CD47 antibody enhances tumor phagocytosis by macrophages, and activation of Natural Killer cells (NK), Dendritic cells (DCs), neutrophils and macrophages (24–26). The gene discussed is SIRPA; the disease is neoplasm.